Genetics and imaging of hepatocellular adenomas: 2011 update

Radiographics

Volumn 31, Issue 6, 2011, Pages 1529-1543

  Katabathina, Venkata S ^a   Menias, Christine O ^c   Shanbhogue, Alampady K P ^a   Jagirdar, Jaishree ^b   Paspulati, Raj Mohan ^d   Prasad, Srinivasa R ^e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA;

CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; GENETICS; GENOTYPE; HUMAN; INFLAMMATION; LIVER ADENOMA; LIVER TUMOR; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; REVIEW;

ADENOMA, LIVER CELL; BETA CATENIN; DIAGNOSIS, DIFFERENTIAL; GENOTYPE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; INFLAMMATION; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MUTATION; PHENOTYPE;

EID: 84857436993     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.316115527     Document Type: Article

References (44)

1. Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976;294(9):470-472.
2. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007;46(3):740-748.
3. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg 2010;27(1):39-45.
4. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006;43(3):515-524.
5. Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009;50(2):481-489.
6. Laumonier H, Cailliez H, Balabaud C, Bioulac-Sage P, Zucman-Rossi J, Trillaud H. Contrast-enhanced ultrasonography to identify the two major subtypes of hepatocellular adenoma. J Hepatol 2010;52 (suppl 1):S223.
7. Lewin M, Handra-Luca A, Arrivé L, et al. Liver adenomatosis: classification of MR imaging features and comparison with pathologic findings. Radiology 2006;241(2):433-440.
8. Laumonier H, Bioulac-Sage P, Laurent C, Zucman- Rossi J, Balabaud C, Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 2008;48(3):808-818.
9. Ronot M, Bahrami S, Calderaro J, et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology 2011;53(4):1182-1191.
10. Bioulac-Sage P, Laumonier H, Laurent C, Zucman-Rossi J, Balabaud C. Hepatocellular adenoma: what is new in 2008. Hepatol Int 2008;2(3):316-321.
11. Paradis V, Champault A, Ronot M, et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology 2007;46(1):140-146.
12. Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009;137(5):1698-1705.
13. Rebouissou S, Amessou M, Couchy G, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009; 457(7226):200-204.
14. Rodriguez C, Grosgeorge J, Nguyen VC, Gaudray P, Theillet C. Human gp130 transducer chain gene (IL6ST) is localized to chromosome band 5q11 and possesses a pseudogene on chromosome band 17p11. Cytogenet Cell Genet 1995;70(1-2):64-67.
15. Spannbauer MM, Trautwein C. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumors. Hepatology 2009;49(4): 1387-1389.
16. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003;14(5):409-426.
17. Bioulac-Sage P, Rebouissou S, Sa Cunha A, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology 2005;128(5): 1211-1218.
18. Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol 2007;13(19):2649-2654.
19. Bluteau O, Jeannot E, Bioulac-Sage P, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002;32(2):312-315.
20. Bacq Y, Jacquemin E, Balabaud C, et al. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology 2003;125(5):1470-1475.
21. Ellard S. Hepatocyte nuclear factor 1 alpha (HNF-1 alpha) mutations in maturity-onset diabetes of the young. Hum Mutat 2000;16(5):377-385.
22. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents: DNA adducts and mutations. J Natl Cancer Inst Monogr 2000;2000(27):75-93.
23. Rebouissou S, Imbeaud S, Balabaud C, et al. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem 2007;282(19):14437-14446.
24. Bioulac-Sage P, Laumonier H, Sa Cunha A, Balabaud C. Hepatocellular adenomas. Liver Int 2009; 29(1):142.
25. Prasad SR, Wang H, Rosas H, et al. Fat-containing lesions of the liver: radiologic-pathologic correlation. RadioGraphics 2005;25(2):321-331.
26. Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. RadioGraphics 2001;21(4): 877-892; discussion 892-894.
27. Ichikawa T, Federle MP, Grazioli L, Nalesnik M. Hepatocellular adenoma: multiphasic CT and histopathologic findings in 25 patients. Radiology 2000; 214(3):861-868.
28. Chen YW, Jeng YM, Yeh SH, Chen PJ. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 2002;36(4 pt 1): 927-935.
29. Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007;45(5):1298-1305.
30. Farges O, Dokmak S. Malignant transformation of liver adenoma: an analysis of the literature. Dig Surg 2010;27(1):32-38.
31. Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V. Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011;60 (1):85-89.
32. Takigawa Y, Brown AM. Wnt signaling in liver cancer. Curr Drug Targets 2008;9(11):1013-1024.
33. Buendia MA. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol 2002;39(5): 530-535.
34. Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis: an entity distinct from liver adenoma? Gastroenterology 1985;89(5):1132-1138.
35. Veteläinen R, Erdogan D, de Graaf W, et al. Liver adenomatosis: re-evaluation of aetiology and management. Liver Int 2008;28(4):499-508.
36. Greaves WO, Bhattacharya B. Hepatic adenomatosis. Arch Pathol Lab Med 2008;132(12):1951-1955.
37. Grazioli L, Federle MP, Ichikawa T, Balzano E, Nalesnik M, Madariaga J. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology 2000;216(2):395-402.
38. Brunt EM, Wolverson MK, Di Bisceglie AM. Benign hepatocellular tumors (adenomatosis) in nonalcoholic steatohepatitis: a case report. Semin Liver Dis 2005;25(2):230-236.
39. Rhim H, Lim HK, Kim YS, Choi D, Lee WJ. Radiofrequency ablation of hepatic tumors: lessons learned from 3000 procedures. J Gastroenterol Hepatol 2008;23(10):1492-1500.
40. van der Sluis FJ, Bosch JL, Terkivatan T, de Man RA, Ijzermans JN, Hunink MG. Hepatocellular adenoma: cost-effectiveness of different treatment strategies. Radiology 2009;252(3):737-746.
41. Ribeiro A, Burgart LJ, Nagorney DM, Gores GJ. Management of liver adenomatosis: results with a conservative surgical approach. Liver Transpl Surg 1998;4(5):388-398.
42. Atwell TD, Brandhagen DJ, Charboneau JW, Nagorney DM, Callstrom MR, Farrell MA. Successful treatment of hepatocellular adenoma with percutaneous radiofrequency ablation. AJR Am J Roentgenol 2005;184(3):828-831.
43. Huurman VA, Stoot JH, van der Linden E, Terpstra OT, Schaapherder AF. Necrosis of a large hepatic tumor after hemorrhage and subsequent selective arterial embolization. World J Gastroenterol 2006;12 (37):6059-6061.
44. Erdogan D, Busch OR, van Delden OM, Ten Kate FJ, Gouma DJ, van Gulik TM. Management of spontaneous haemorrhage and rupture of hepatocellular adenomas: a single centre experience. Liver Int 2006;26(4):433-438.